Literature DB >> 22575811

Evaluation of the use of a rapid diagnostic consultation of lung cancer. Delay time of diagnosis and therapy.

Javier Hueto Pérez De Heredia1, Pilar Cebollero Rivas, José Antonio Cascante Rodrigo, Isabel Andrade Vela, Idoya Pascal Martínez, Joan Boldú Mitjans, Víctor Manuel Eguía Astibia.   

Abstract

OBJECTIVE: To analyze the results obtained in a lung cancer screening program since its inception five years ago regarding correct referrals, diagnostic and therapeutic delay times and days of hospitalization. To compare the diagnostic-therapeutic delays and hospital stays with those obtained in patients evaluated with the standard system. PATIENTS AND METHODS: Included for study were all those patients evaluated in our Lung Cancer Screening Program (LCSP) in the last five years. For the cases with LC, we recorded the dates the patients were referred to a specialist, the first consultation, diagnostic tests, stage, start of treatment and days of hospitalization. We compared these same data with lung cancer patients who did not partake in the LCSP and were diagnosed between October 2008 and October 2010.
RESULTS: We evaluated 179 patients remitted to the LCSP, which represented 26.7% of the consultations; 166 (92.7%) of the referrals were correct, out of which 44.5% were LC. In 75.6% of these, the entire study was completed in the outpatient setting, and more than 85% of the cases met the current recommendations related with diagnostic-therapeutic delays. When these results were compared with the non-LCSP group (n=151), differences were found in the data for hospitalizations: there was a lower percentage of hospitalizations (P<.0001) and shorter hospital stays (P<.0001) in the LCSP group. There were no differences between the two groups for diagnostic or therapeutic delays.
CONCLUSION: In our setting, lung cancer screening programs allow for cancer studies to be carried out in the outpatient consultations in a large percentage of cases, and within the time periods recommended by current guidelines. In spite of this fact, we have detected that these programs are underused.
Copyright © 2011 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22575811     DOI: 10.1016/j.arbres.2012.03.009

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  4 in total

Review 1.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

2.  Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units.

Authors:  Sonia Blanco-Prieto; Loretta De Chiara; Mar Rodríguez-Girondo; Lorena Vázquez-Iglesias; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar; María Isabel Botana-Rial; María Páez de la Cadena
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

3.  Impact of the delay to start treatment in patients with lung cancer treated in a densely populated area of Brazil.

Authors:  Fernando Conrado Abrao; Igor Renato Louro Bruno de Abreu; Roberto Odebrecht Rocha; Felipe Dourado Munhoz; João Henrique Godoy Rodrigues; Riad Naim Younes
Journal:  Clinics (Sao Paulo)       Date:  2017-11       Impact factor: 2.365

4.  SIRT3 acts as a novel biomarker for the diagnosis of lung cancer: A retrospective study.

Authors:  Feng Tao; Chao Gu; Na Li; Ying Ying; Yongzhi Feng; Dan Ni; Qi Zhang; Qinfeng Xiao
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.